Gynaecological Cancer Research Group

Home
Australia
Randwick, NSW
Gynaecological Cancer Research Group

Improving outcomes for people with gynaecological diseases using cutting-edge and ethically minded science.

Improving outcomes for people with ovarian and endometrial cancer, and endometriosis using cutting-edge and ethically minded science.

03/07/2025

Congratulations to our PhD candidate Sumyukta Garikapati for winning the People’s Choice Award at the UNSW Medicine & Health 3 Minute Thesis Faculty Heats! 🏆 🧫

Her presentation - “The recipe for better research: optimising ovarian and endometrial cancer modelling” - captured the crowd and showcased the innovative cancer research happening right here in our lab. ✨

Next stop: the UNSW finals in September - go Sumyukta! 🧠 👏🏼

23/06/2025

Today we had the pleasure of welcoming back to our lab! 🧬🧪
Since his last visit in 2022, our team has made some exciting strides in gynaecological cancer and endometriosis research, and it was a privilege to share some of our latest advancements with him.

We’re grateful for his continued interest and support as we work to improve outcomes for everyone affected by gynaecological diseases.

21/05/2025

New publication live now!

This review article highlights that endometriosis ≠ endometrium. Nearly half of “endometriosis” datasets misrepresent the disease by using eutopic endometrial tissue. For real progress in endometriosis treatment, we need the right models and samples that reflect the true complexity of the disease.

Discover the full article by following the link in our bio!

30/04/2025

🔬New publication live now!

Our latest study in collaboration with
and highlights the promising efficacy of NBE-002, a ROR1-targeted antibody-drug conjugate (ADC), in treating high-grade serous ovarian cancer.

We observed potent cytotoxic activity in ROR1-expressing models both in vitro and in vivo. Notably, combining NBE-002 with carboplatin led to greater anti-tumour effects in platinum-resistant models.

These findings support the clinical development of ROR1-targeting ADCs for patients with high ROR1-expressing ovarian cancers.

👀 Read the full article, link in our bio.

19/03/2025

🧬 We are hiring!

We have an exciting opportunity for a research assistant to join the GCRG.

Using cell-free DNA and molecular biology techniques, the research assistant will play a key role in the development of an early detection test for ovarian cancer.

This role also offers the opportunity to work closely with clinicians, biospecimen donors, and other researchers.

Interested in contributing towards our innovative ovarian cancer research? Visit https://external-careers.jobs.unsw.edu.au/cw/en/job/531283/research-assistant.

05/03/2025

It’s 🎗️

Endometriosis is a common chronic condition. Between 2021-2022, more than 40,000 endo-related hospitalisations were estimated in Australia.

Currently, non-invasive diagnostic and effective treatment strategies are limited, highlighting the need for innovative research.

is clinically diverse, with symptoms and degrees of severity varying from person to person.

Eliminating the stigma and dismissal surrounding pelvic pain is the first step to overcoming diagnostic delays (7 years on average from disease onset). Know your body, know the symptoms, and know when to seek medical help.

🔬Photos supplied by Kate Gunther. Stay tuned to learn how she is tackling the endo space.

11/02/2025

Today we celebrate the outstanding women and all who identify as women in STEMM.

Our commitment to diversity and equality drives our advocacy and support for women and gender-diverse individuals in science and medicine.

We recognise those dedicated to researching and providing clinical care for gynaecological conditions, a field that remains overlooked and underfunded — barriers that limit progress in patient care.

04/02/2025

Behind each medical diagnosis is one person’s unique and personal story.

On this , we honour each unique journey in the fight against cancer.

By uniting in empathy and embracing each individual’s differences, people affected by cancer can be placed at the very centre of clinical care.

Together, we are .

02/02/2025

It’s .

is difficult to diagnose early and has one of the poorest prognoses among women and those reported female at birth, earning itself the name ‘silent killer’.

Knowing these common symptoms and seeking medical help if you experience them can help in finding signs of ovarian cancer early.

For more information, visit our website through the link in our bio.

And stay tuned to learn more about what our team is doing to combat the impact of ovarian cancer.

29/01/2025

Diagnoses of is often delayed by up to 7 years on average from its onset.

To combat this, our team is investigating potential blood-based for the detection of endometriosis.

We now seek blood donations from volunteers who menstruate and are undergoing investigation for endometriosis.

To be eligible:
- Be over 18 years old
- Menstruate
- Be undergoing investigation for endometriosis
- Not be currently using hormonal therapies
- Not be pregnant or lactating
- Have no personal history of cancer

For more info or to participate, email Brigitte at earlydetection@unsw.edu.au

09/01/2025

New article out now ✨

With the rapid increase in cases of globally, there is a critical need to identify new pathways and targets to improve outcomes for women with this disease, particularly those with the most aggressive subtypes.

In collaboration with A/Prof. O’Mara and A/Prof Glubb from , we have independently identified the small molecule GZD824 to target oncogenic pathways of interest in endometrial cancer.

This study has demonstrated the anti-cancer potential of GZD824 and supported the potential combination therapy of GZD824 and immune checkpoint inhibitors in endometrial cancer.

Discover the full study, link in our bio!

08/01/2025

New publication out now!

With the rapid increase in cases of globally, there is a critical need to identify new pathways and targets to improve outcomes for individuals with this disease, particularly those with the most aggressive subtypes.

In collaboration with Dr O’Mara and A/Prof Glubb from , we have independently identified the small molecule GZD824 to target oncogenic pathways of interest in endometrial cancer.

This study has demonstrated the anti-cancer potential of GZD824 and supported the potential combination therapy of GZD824 and immune checkpoint inhibitors in endometrial cancer.

Discover the full study, link in our bio!

Address

Randwick, NSW

Website

https://www.gyncancerresearch.org/

Alerts

Be the first to know and let us send you an email when Gynaecological Cancer Research Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.